Evaluating Carbocisteine for Nonalcoholic Fatty Liver Disease
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
This study is testing if Carbocisteine can help adults with Nonalcoholic Fatty Liver Disease improve their liver health when combined with lifestyle changes like diet and exercise.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT06863376 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the safety and efficacy of Carbocisteine in treating patients with Nonalcoholic Fatty Liver Disease (NAFLD). The study involves administering Carbocisteine alongside lifestyle interventions such as physical activity and calorie restriction. Participants will be adult patients diagnosed with fatty liver through ultrasound, and the trial will monitor their response to the treatment. The goal is to determine if Carbocisteine can improve liver health in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients over 18 years old diagnosed with fatty liver disease.
Not a fit: Patients with other chronic liver diseases or significant alcohol use may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new pharmacological option for managing Nonalcoholic Fatty Liver Disease.
How similar studies have performed: While there is ongoing research into pharmacological treatments for NAFLD, the specific use of Carbocisteine in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography Exclusion Criteria: * Pregnant and/or lactating women * Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women) * Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis. * patients suffering from chronic kidney disease, and hyper/hypoparathyroidism * Hypersensitivity to carbocistiene.
Where this trial is running
Tanta
- Tanta Unuversity — Tanta, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.